Drugmaker Execs Hid Approval Process Roadblocks, Suit Says

By Gina Kim · March 26, 2025, 7:25 PM EDT

A Sage Therapeutics Inc. investor sued the company's executives in New York federal court Wednesday alleging they hid significant setbacks affecting the regulatory approval for its drug candidates intended to treat mood...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Zhu v. Greene et al

Case Number

Court

New York Southern

Nature of Suit

Stockholders Suits

Date Filed

March 26, 2025

Recent Articles By Gina

April 17, 2025
Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal
April 17, 2025
9th Circ. Revives Defect Suit Against CR Bard Over Clot Filter
April 03, 2025
Amazon, Biotech Net $1.9M Win Against Fake Supplement Sellers
March 26, 2025
Healthcare Providers To Pay $63M Over False Spinal Diagnoses
March 11, 2025
Kenvue Unit Can't Nix BIPA Suit Over Neutrogena Skin360 App
February 04, 2025
McKesson, Others Beat Indirect Drug Reseller Price-Fix Suit
February 03, 2025
Apple Seeks Bench Trial Win In Masimo's Trade Secret Suit
January 23, 2025
GoodRx, PBMs Sued Over Alleged Generics Price-Fix Scheme
January 17, 2025
PE Firm Resolves FTC's Antitrust Anesthesia Roll-Up Case
January 10, 2025
Masimo, Apple Fight Over Watch IP In Post-Bench Trial Briefs